Systagenix introduces ‘WoundChek’ test
England, January 25, 2012
Wound care specialist Systagenix said it has introduced the world's first rapid, point-of-care diagnostic test developed specifically for chronic wounds.
The new test, WoundChek Protease Status, has the potential to revolutionise wound care by enabling early, targeted intervention and cost-effective use of advanced therapies designed to modulate protease activity, the company said in a statement.
According to Systagenix, the test will be initially introduced across Europe, South Africa and the Middle East. The company also confirmed that commercial shipment of the first WoundChek Protease Status test kits has commenced.
Developed by Systagenix Wound Management in collaboration with Alere, and designed to form part of routine wound assessment, the test is easy-to-use and provides results in 15 minutes at the point-of-care.
This enables the test to immediately influence treatment decisions and help clinicians target advanced wound care therapies more effectively by identifying when elevated protease activity (EPA) exists in chronic wounds.
A recently published study showed that chronic wounds with EPA have a 90 per cent probability they will not heal without appropriate intervention.
Louise Hambrook, Systagenix global category director for diagnostics, said: “We’re delighted that leading clinicians are recognising the potential impact WoundChek Protease Status will have on the way wound care is provided."
"The damaging effect of EPA on wound healing has been widely documented over the years, but it is only now that we can appreciate and begin to identify its full impact," he added.
Established in 2008, following the acquisition of Johnson & Johnson’s advanced wound care business, Systagenix supplies over 20 million advanced wound dressings per month into over 100 countries worldwide, it said. – TradeArabia News Service